Stabilitech Ltd, which specialises in technology for stabilising protein-based drugs and vaccines, has signed a $4 million contract with the US Defense Threat Reduction Agency (DTRA) to work on stabilising two biodefense vaccines using the company’s vaccine stabilisation technology.
London-based Stabilitech will apply its proprietary formulation principles to stabilise an adenovirus-vectored and an adjuvanted vaccine. The two are being developed for potential use against a key bacterial pathogen target.
The goal of the DTRA is to find technologies that will successfully allow the stockpiling of key biodefense vaccines, protecting vaccines against both heat and freeze damage and allowing them to be stored at ambient temperatures.
Barbara Domayne-Hayman, Stabilitech’s CEO, said, “We are very pleased to have been selected by DTRA to work on these key projects for the US Department of Defense. We believe the work will demonstrate the broad applicability of our stabilisation technology and enable the DTRA to achieve its goals for these important biodefense vaccines. In addition, this non-dilutive funding is important as Stabilitech continues to grow.”